Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

398.00p
   
  • Change Today:
    -10.50p
  • 52 Week High: 445.00p
  • 52 Week Low: 166.80p
  • Currency: UK Pounds
  • Shares Issued: 105.36m
  • Volume: 91,279
  • Market Cap: £419.33m
  • RiskGrade: 125

Boost for Oxford Biomedica as Novartis files for further blood cancer indication

By Oliver Haill

Date: Tuesday 31 Oct 2017

LONDON (ShareCast) - (ShareCast News) - Oxford Biomedica received a boost as Novartis announced that it has filed for approval of its Kymriah drug for a second blood cancer indication.
Kymriah is the main potential driver of revenues and profits for Oxford Biomedica through its deal as the sole manufacturer of the lentiviral vectors used to generate Kymriah.

Novartis said on Tuesday it had applied to the US Food & Drug Administration for Kymriah in adult patients suffering from a relapsed or refractory diffuse large B-cell lymphoma who are ineligible for an autologous stem cell transplant.

Kymriah was approved by the FDA in August in the smaller indication of paediatric acute lymphoblastic leukemia, which was the first-ever chimeric antigen receptor T cell (CAR-T) therapy approved by the US regulator.

Novartis also plans to apply to European authorities to market DLBCL this year.

Novartis noted that DLBCL is a significantly larger patient pool with US & EU relapsed/refractory DLBCL incidence of around 50,000 per year versus 2,200 for ALL.

Elsewhere, Oxford Biomedica got a second piece of good news as Sanofi chose not to exercise its option on Voyager's VY-AADC gene therapy product for Parkinsons, which is a potential competitor to OXB-102, Oxford BioMedica's own gene therapy pipeline candidate for Parkinsons.

According to reports, Sanofi's decision was due to the fact that its existing deal with Voyager did not include US rights.

Sanofi has a number of other existing gene therapy projects with Oxford BioMedica, noted analysts at Peel Hunt, also suggesting that further deals, whether for lentiviral vector supply and/or gene therapy partnerships, "are important potential catalysts for Oxford BioMedica and we await further updates with interest".

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price 398.00p
Change Today -10.50p
% Change -2.57 %
52 Week High 445.00p
52 Week Low 166.80p
Volume 91,279
Shares Issued 105.36m
Market Cap £419.33m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.96% below the market average31.96% below the market average31.96% below the market average31.96% below the market average31.96% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Price Trend
88.50% above the market average88.50% above the market average88.50% above the market average88.50% above the market average88.50% above the market average
96.00% above the sector average96.00% above the sector average96.00% above the sector average96.00% above the sector average96.00% above the sector average
Income Not Available
Growth
52.8% below the market average52.8% below the market average52.8% below the market average52.8% below the market average52.8% below the market average
52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 5
Sell 0
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 31-Oct-2024

Time Volume / Share Price
16:40 15,468 @ 397.43p
16:35 18,278 @ 398.00p
16:35 7 @ 398.00p
16:35 357 @ 398.00p
16:35 242 @ 398.00p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page